170 related articles for article (PubMed ID: 16267747)
1. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
[No Abstract] [Full Text] [Related]
2. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
3. [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
Sugito M; Tsukada J; Higashi T; Ohta T; Matsuura A; Kubota A; Mizobe T; Mouri F; Morimoto H; Tanaka Y
Rinsho Ketsueki; 2005 Nov; 46(11):1226-8. PubMed ID: 16440809
[TBL] [Abstract][Full Text] [Related]
4. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
7. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
8. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
9. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
Rosado MF; Donna E; Ahn YS
J Clin Oncol; 2003 Aug; 21(16):3171-3. PubMed ID: 12915610
[No Abstract] [Full Text] [Related]
10. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
[TBL] [Abstract][Full Text] [Related]
12. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
[No Abstract] [Full Text] [Related]
13. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
Anthony N; Shanks J; Terebelo H
Leuk Res; 2010 Sep; 34(9):1250-1. PubMed ID: 20646761
[No Abstract] [Full Text] [Related]
14. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
15. Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia.
Chng WJ; Tan LH
Leuk Res; 2005 Jun; 29(6):719-20. PubMed ID: 15863215
[No Abstract] [Full Text] [Related]
16. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
[TBL] [Abstract][Full Text] [Related]
17. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
[No Abstract] [Full Text] [Related]
18. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
Vernon MR; Pearson L; Atallah E
J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
[No Abstract] [Full Text] [Related]
19. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
20. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
[No Abstract] [Full Text] [Related]
[Next] [New Search]
